ECSP18081437A - Forma polimorfa de n–{6–(2–hidroxipropan–2–il)–2–[2–(metilsulfonil)etil]–2h–indazol–5–il}–6–(trifluorometil)piridin–2–carboxamida - Google Patents

Forma polimorfa de n–{6–(2–hidroxipropan–2–il)–2–[2–(metilsulfonil)etil]–2h–indazol–5–il}–6–(trifluorometil)piridin–2–carboxamida

Info

Publication number
ECSP18081437A
ECSP18081437A ECSENADI201881437A ECDI201881437A ECSP18081437A EC SP18081437 A ECSP18081437 A EC SP18081437A EC SENADI201881437 A ECSENADI201881437 A EC SENADI201881437A EC DI201881437 A ECDI201881437 A EC DI201881437A EC SP18081437 A ECSP18081437 A EC SP18081437A
Authority
EC
Ecuador
Prior art keywords
hydroxypropan
indazol
methylsulfonyl
carboxamide
ethyl
Prior art date
Application number
ECSENADI201881437A
Other languages
English (en)
Inventor
Tobias Thaler
Johannes Platzek
Nicolas Guimond
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of ECSP18081437A publication Critical patent/ECSP18081437A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86Hydrazides; Thio or imino analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a formas cristalinas de N–{6–(2–hidroxipropan–2–il)–2–[2–(metilsulfonil)etil]–2H–indazol–5–il}–6–(trifluorometil)piridin–2–carboxamida, procesos para su preparación, composiciones farmacéuticas que las comprenden y su utilización en el control de trastornos.
ECSENADI201881437A 2016-04-29 2018-10-29 Forma polimorfa de n–{6–(2–hidroxipropan–2–il)–2–[2–(metilsulfonil)etil]–2h–indazol–5–il}–6–(trifluorometil)piridin–2–carboxamida ECSP18081437A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16167652 2016-04-29

Publications (1)

Publication Number Publication Date
ECSP18081437A true ECSP18081437A (es) 2018-11-30

Family

ID=55860769

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201881437A ECSP18081437A (es) 2016-04-29 2018-10-29 Forma polimorfa de n–{6–(2–hidroxipropan–2–il)–2–[2–(metilsulfonil)etil]–2h–indazol–5–il}–6–(trifluorometil)piridin–2–carboxamida

Country Status (43)

Country Link
US (2) US10759758B2 (es)
EP (4) EP3448846B1 (es)
JP (2) JP7068188B2 (es)
KR (2) KR102373017B1 (es)
CN (3) CN113185457A (es)
AR (1) AR108245A1 (es)
AU (2) AU2017256626B2 (es)
BR (2) BR112018072246A2 (es)
CA (2) CA3022332A1 (es)
CL (2) CL2018003087A1 (es)
CO (2) CO2018011622A2 (es)
CU (1) CU20180131A7 (es)
DK (2) DK3448846T3 (es)
DO (1) DOP2018000237A (es)
EA (2) EA201892415A1 (es)
EC (1) ECSP18081437A (es)
ES (2) ES2966772T3 (es)
FI (1) FI3448848T3 (es)
GE (1) GEP20217214B (es)
HR (2) HRP20231454T1 (es)
HU (2) HUE064389T2 (es)
IL (2) IL262414B2 (es)
JO (2) JOP20170100B1 (es)
LT (2) LT3448848T (es)
MA (1) MA44759B1 (es)
MX (2) MX2018013235A (es)
MY (2) MY190319A (es)
NI (1) NI201800112A (es)
PE (1) PE20190107A1 (es)
PH (1) PH12018502289A1 (es)
PL (2) PL3448846T3 (es)
PT (2) PT3448846T (es)
RS (2) RS62112B1 (es)
SA (1) SA518400333B1 (es)
SG (2) SG11201808566WA (es)
SI (2) SI3448846T1 (es)
SV (1) SV2018005775A (es)
TN (1) TN2018000352A1 (es)
TW (2) TWI649314B (es)
UA (2) UA124103C2 (es)
UY (2) UY37216A (es)
WO (2) WO2017186703A1 (es)
ZA (1) ZA201808057B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
ES2966772T3 (es) * 2016-04-29 2024-04-24 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida
ES2801800T3 (es) 2016-04-29 2021-01-13 Bayer Pharma AG Síntesis de indazoles
CN109152771B (zh) 2016-06-01 2022-07-19 拜耳医药股份有限公司 2-取代的吲唑用于治疗和预防自身免疫疾病的用途
SG11201809470RA (en) * 2016-06-01 2018-11-29 Bayer Animal Health Gmbh Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
KR20210024543A (ko) 2018-06-25 2021-03-05 치아타이 티안큉 파마수티컬 그룹 주식회사 IRAK4 억제제로서의 이소티아졸로[5,4-d]피리미딘 화합물
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
AU2021353004A1 (en) 2020-09-30 2023-04-13 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
CN114469979B (zh) * 2021-12-15 2024-04-09 安徽贝克生物制药有限公司 一种核糖核苷类似物的药物组合物、吸入剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
EP2045253A4 (en) 2006-06-29 2013-01-23 Nissan Chemical Ind Ltd alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient
MX2009002377A (es) 2006-09-07 2009-03-13 Biogen Idec Inc Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
JP5620393B2 (ja) 2009-10-09 2014-11-05 田辺三菱製薬株式会社 脳梗塞治療薬
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
PL2655357T3 (pl) 2010-12-20 2016-12-30 Pochodne triazolowe indazolilowe jako inhibitory irak
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9126984B2 (en) * 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
EP3066090A1 (en) 2013-11-08 2016-09-14 iTeos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10160753B2 (en) 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3288558B1 (en) * 2015-04-30 2022-05-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
MX2018000512A (es) 2015-07-15 2018-04-13 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de la cinasa 4 asociada al receptor de interlucina 1 (irak-4).
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
ES2966772T3 (es) 2016-04-29 2024-04-24 Bayer Pharma AG Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol-5-il}-6-(trifluorometil)piridin-2-carboxamida
ES2801800T3 (es) 2016-04-29 2021-01-13 Bayer Pharma AG Síntesis de indazoles
CN109152771B (zh) 2016-06-01 2022-07-19 拜耳医药股份有限公司 2-取代的吲唑用于治疗和预防自身免疫疾病的用途
SG11201809470RA (en) 2016-06-01 2018-11-29 Bayer Animal Health Gmbh Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals

Also Published As

Publication number Publication date
WO2017186703A1 (en) 2017-11-02
NZ746469A (en) 2023-08-25
LT3448848T (lt) 2023-11-27
PH12018502289B1 (en) 2019-07-15
ZA201808057B (en) 2023-05-31
TW201738230A (zh) 2017-11-01
DK3448848T3 (da) 2023-12-18
IL262659A (en) 2018-12-31
NZ746526A (en) 2023-08-25
AU2017256626A1 (en) 2018-10-11
MX2018013234A (es) 2019-02-13
MX2018013235A (es) 2019-02-13
CN113185457A (zh) 2021-07-30
JP2019514923A (ja) 2019-06-06
JP2019514922A (ja) 2019-06-06
PH12018502289A1 (en) 2019-07-15
SI3448846T1 (sl) 2021-09-30
CA3022324A1 (en) 2017-11-02
JOP20170100B1 (ar) 2022-03-14
SG11201808566WA (en) 2018-11-29
US10759758B2 (en) 2020-09-01
US20190106407A1 (en) 2019-04-11
UY37216A (es) 2018-06-29
MY190319A (en) 2022-04-13
AU2017256626B2 (en) 2021-05-27
SA518400333B1 (ar) 2022-06-05
EP3448846A1 (en) 2019-03-06
EP3448846B1 (en) 2021-05-26
CN109071489A (zh) 2018-12-21
BR112018072246A2 (pt) 2019-02-12
CL2018003087A1 (es) 2019-02-22
JP7068188B2 (ja) 2022-05-16
SV2018005775A (es) 2019-02-07
EP4275755A3 (en) 2023-12-27
SG11201808108XA (en) 2018-10-30
CO2018011622A2 (es) 2018-11-22
HUE064389T2 (hu) 2024-03-28
CN109415340B (zh) 2021-10-12
MY187184A (en) 2021-09-09
AU2017257211B2 (en) 2021-05-27
AU2017257211A1 (en) 2018-10-11
RS64928B1 (sr) 2023-12-29
IL262414B2 (en) 2023-10-01
EP3448848A1 (en) 2019-03-06
HUE056460T2 (hu) 2022-02-28
IL262414A (en) 2018-12-31
TW201738232A (zh) 2017-11-01
UY37215A (es) 2017-11-30
ES2966772T3 (es) 2024-04-24
PT3448846T (pt) 2021-08-19
IL262659B (en) 2021-05-31
UA123169C2 (uk) 2021-02-24
EA038035B1 (ru) 2021-06-25
EA201892430A1 (ru) 2019-05-31
MA44759B1 (fr) 2024-01-31
US10501417B2 (en) 2019-12-10
EA201892415A1 (ru) 2019-05-31
BR112018072242A2 (pt) 2019-04-09
AR108245A1 (es) 2018-08-01
CN109071489B (zh) 2020-07-10
KR102373220B1 (ko) 2022-03-11
UA124103C2 (uk) 2021-07-21
CA3022332A1 (en) 2017-11-02
EP3448848B1 (en) 2023-09-27
TN2018000352A1 (en) 2020-06-15
US20190112270A1 (en) 2019-04-18
NI201800112A (es) 2019-08-29
PT3448848T (pt) 2024-01-02
DOP2018000237A (es) 2018-11-15
LT3448846T (lt) 2021-07-26
SI3448848T1 (sl) 2024-01-31
KR102373017B1 (ko) 2022-03-11
TWI657084B (zh) 2019-04-21
PL3448848T3 (pl) 2024-03-11
CU20180131A7 (es) 2019-06-04
MA44759A (fr) 2019-03-06
JOP20170099B1 (ar) 2022-03-14
HRP20231454T1 (hr) 2024-03-01
JP6954924B2 (ja) 2021-10-27
CO2018011644A2 (es) 2018-11-13
PE20190107A1 (es) 2019-01-15
IL262414B1 (en) 2023-06-01
PL3448846T3 (pl) 2021-12-20
EP4275754A3 (en) 2023-12-27
FI3448848T3 (fi) 2023-12-21
RS62112B1 (sr) 2021-08-31
CL2018003088A1 (es) 2019-01-25
EP4275755A2 (en) 2023-11-15
ES2883298T3 (es) 2021-12-07
CN109415340A (zh) 2019-03-01
KR20180137497A (ko) 2018-12-27
KR20180137496A (ko) 2018-12-27
EP4275754A2 (en) 2023-11-15
WO2017186689A1 (en) 2017-11-02
HRP20211072T1 (hr) 2021-10-01
TWI649314B (zh) 2019-02-01
GEP20217214B (en) 2021-01-25
DK3448846T3 (da) 2021-08-16

Similar Documents

Publication Publication Date Title
DOP2018000237A (es) Forma polimorfa de n–{6–(2–hidroxipropan–2–il)–2–[2–(metilsulfonil)etil]–2h–indazol–5–il}–6–(trifluorometil)piridin–2–carboxamida
NI201800111A (es) Formas cristalinas de n-[2-3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6- (trifluorometil)-piridin-2-carboxamida.
CO2018000113A2 (es) Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
BR112018006243A2 (pt) formas de cristal de mononucleotídeo de beta-nicotinamida
EA201991293A1 (ru) Получение новых препаратов на основе бета-лактоглобулина и связанные с ними способы, варианты применения и продукты питания
CR20150448A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
CR20190122A (es) Formulaciones que contienen fluopiram para el control de nemátodos
DK3380471T3 (da) Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser
UY35746A (es) Derivados de fenilalanina sustituidos
CO2017007249A2 (es) Modificación cristalina de propanil
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
CL2019000027A1 (es) Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes.
CO2018005354A2 (es) Derivados novedosos de diamino piridina
DK3544630T3 (da) Ernæringssammensætning med resistent stivelse som er egnet til behandling af neoplastiske sygdomme
TWD178718S (zh) 跳欄